keyword
MENU ▼
Read by QxMD icon Read
search

Trulicity

keyword
https://www.readbyqxmd.com/read/29094890/dulaglutide-trulicity-for-type-2-diabetes-mellitus
#1
Emma Pace, Jeffrey Tingen
No abstract text is available yet for this article.
October 15, 2017: American Family Physician
https://www.readbyqxmd.com/read/27313432/dulaglutide-trulicity-the-third-once-weekly-glp-1-agonist
#2
Lillian L Smith, Juan F Mosley, Crystal Parke, Jamal Brown, Lillian S Barris, Linh D Phan
Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist for type-2 diabetes.
June 2016: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/27311248/-dulaglutide-trulicity%C3%A2-a-new-once-weekly-agonist-of-glucagon-like-peptide-1-receptors-for-type-2-diabetes
#3
COMPARATIVE STUDY
A J Scheen
Dulaglutide (Trulicity®) is a new once-weekly agonist of Glucagon-Like Peptide-1 (GLP-1) receptors indicated in the treatment of type 2 diabetes. Phase III clinical trials in AWARD programme demonstrated the efficacy and safety of dulaglutide in patients with type 2 diabetes treated by diet and exercise, metformin, a combination of metformin and a sulfonylurea or metformin and pioglitazone or even by supplements of prandial insulin. In the AWARD programme, dulaglutide (subcutaneous 0.75 or 1.5 mg once weekly) exerted a greater glucose-lowering activity than metformin, sitagliptin, exenatide or insulin glargine, and was non-inferior to liraglutide 1...
March 2016: Revue Médicale de Liège
https://www.readbyqxmd.com/read/27217788/advances-in-the-treatment-of-type-2-diabetes-impact-of-dulaglutide
#4
REVIEW
Angela M Thompson, Jennifer M Trujillo
The purpose of this review is to provide a review of current data of the most recently approved glucagon-like peptide (GLP)-1-receptor agonist, dulaglutide, in the treatment of type 2 diabetes. To complete this, a PubMed search was performed to identify manuscripts published from 1947 to July 2015. The search terms "Trulicity", "dulaglutide", and "LY2189265" were utilized, and publications were included if they evaluated the pharmacology, pharmacokinetics, efficacy, safety, or patient-reported outcomes of dulaglutide...
2016: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/26629278/trulicity-dulaglutide-a-new-glp-1-receptor-agonist-once-weekly-subcutaneous-injection-approved-for-the-treatment-of-patients-with-type-2-diabetes
#5
Loretta Fala
No abstract text is available yet for this article.
March 2015: American Health & Drug Benefits
https://www.readbyqxmd.com/read/26423061/dulaglutide-a-review-in-type-2-diabetes
#6
REVIEW
Celeste B Burness, Lesley J Scott
Dulaglutide (Trulicity™) is a once-weekly subcutaneously administered glucagon-like peptide-1 (GLP-1) receptor agonist produced by recombinant DNA technology and approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2DM). In randomized controlled trials in patients with T2DM, dulaglutide monotherapy was noninferior to once-daily subcutaneous liraglutide monotherapy and significantly more effective than oral metformin monotherapy in improving glycemic control at 26 weeks...
December 2015: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/25657615/dulaglutide-an-evidence-based-review-of-its-potential-in-the-treatment-of-type-2-diabetes
#7
REVIEW
Krystal L Edwards, Molly G Minze
INTRODUCTION: As the prevalence of type 2 diabetes mellitus (T2DM) is anticipated to continue to rise worldwide, so too are the treatment options also continuing to expand. Current guidelines recommend individualized treatment plans which allow for provider choice and diversity of pharmacotherapeutic regimens. The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is rapidly expanding, with dulaglutide (Trulicity™) as a once-weekly agent recently approved. AIMS: This article examines the evidence currently available on the efficacy and safety of dulaglutide for use in T2DM...
2015: Core Evidence
https://www.readbyqxmd.com/read/25516691/pharmaceutical-approval-update
#8
Kunj Gohil
Ledipasvir/sofosbuvir (Harvoni) for hepatitis C virus genotype 1 infection; dulaglutide (Trulicity) for glycemic control in type-2 diabetes; netupitant/palonosetron (Akynzeo) for prevention of nausea and vomiting related to chemotherapy; and naloxegol (Movantik) for opioid-induced constipation in patients with chronic noncancer pain.
December 2014: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/25367716/dulaglutide-first-global-approval
#9
REVIEW
Mark Sanford
Dulaglutide (Trulicity™) is a long-acting, glucagon-like peptide-1 (GLP-1) receptor agonist that has been developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. It consists of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker. The subcutaneous formulation is approved for use in type 2 diabetes in the US, has been recommended for approval in the EU in this indication, and is under regulatory review in other countries...
November 2014: Drugs
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"